Hepatitis C is curable in more than 95% of patients with current direct-acting antiviral therapy — yet an estimated 60% of the 2.4 million Americans living with HCV remain unaware of their diagnosis. The Baby Boomer cohort, born between 1945 and 1965, carries disproportionate burden from unscreened blood products and remains significantly undertreated. For a condition this curable, the treatment gap is a clinical problem.
AAVBC's Hepatitis C Quick Reference Guide gives primary care clinicians a structured reference for screening, treatment initiation, and longitudinal documentation of chronic HCV. It covers universal screening protocols, DAA therapy documentation, ICD-10 coding distinctions between active infection and post-cure status, cirrhosis and extrahepatic manifestation coding, and MEAT documentation standards — grounded in current AASLD and IDSA guideline evidence.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of hepatitis C — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Hepatitis C is curable in more than 95% of patients with current direct-acting antiviral therapy — yet an estimated 60% of the 2.4 million Americans living with HCV remain unaware of their diagnosis. The Baby Boomer cohort, born between 1945 and 1965, carries disproportionate burden from unscreened blood products and remains significantly undertreated. For a condition this curable, the treatment gap is a clinical problem.
AAVBC's Hepatitis C Quick Reference Guide gives primary care clinicians a structured reference for screening, treatment initiation, and longitudinal documentation of chronic HCV. It covers universal screening protocols, DAA therapy documentation, ICD-10 coding distinctions between active infection and post-cure status, cirrhosis and extrahepatic manifestation coding, and MEAT documentation standards — grounded in current AASLD and IDSA guideline evidence.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of hepatitis C — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
